Cross-over Study to Prove Bioequivalence Between Two Oral Formulations of Levonorgestrel (LEVEQ-1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01096485
Recruitment Status : Completed
First Posted : March 31, 2010
Last Update Posted : June 11, 2013
Information provided by:

March 30, 2010
March 31, 2010
June 11, 2013
February 2009
March 2009   (Final data collection date for primary outcome measure)
  • Least square estimator of average maximum plasmatic concentration (log transformed) [ Time Frame: After 2 months ]
  • Least square estimator of area under the pharmacokinetic curve (log transformed) [ Time Frame: After 2 months ]
Same as current
Complete list of historical versions of study NCT01096485 on Archive Site
  • Time at which maximum concentration is reached [ Time Frame: After 2 months ]
  • Area under the pharmacokinetic curve from time=0 to time of last blood sample [ Time Frame: After 2 months ]
  • Clearance constant of plasmatic concentration of study drug [ Time Frame: After 2 months ]
  • Half life of plasmatic concentration of study drug [ Time Frame: After 2 months ]
  • Adverse events collection [ Time Frame: Up to 8 weeks ]
Same as current
Not Provided
Not Provided
Cross-over Study to Prove Bioequivalence Between Two Oral Formulations of Levonorgestrel
Open-label, Randomized, Crossover Study to Compare the Bioavailability of One Coated Tablet of Opxion® (Levonorgestrel 1.5 mg From Bayer de Mexico) vs. Two Tablets of Postday® (Levonorgestrel 0.75 mg From Investigacion Farmaceutica), in Healthy Volunteers
A single dose, two treatments (Postday and Opxion), two periods, two sequences, crossover, randomized, prospective design was chosen with a washout of 21 days between the two study periods. Treatment groups were balanced with the same number of male healthy volunteers who were randomly assigned to the study drug administration sequences.
Not Provided
Phase 1
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
  • Contraception
  • Contraception, Postcoital
  • Drug: Levonorgestrel Emergency Pill (BAY86-5028/Opxion)
    Single dose of 1.5 mg coated tablet
  • Drug: Levonorgestrel (Postday)
    Single dose of two 0.75 mg tablets
  • Experimental: Arm 1
    Intervention: Drug: Levonorgestrel Emergency Pill (BAY86-5028/Opxion)
  • Active Comparator: Arm 2
    Intervention: Drug: Levonorgestrel (Postday)
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
March 2009
March 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy male volunteers age between 18 and 55 years old with normal vital signs, electrocardiogram (ECG), blood chemistry, liver function profile and urinalysis.

Exclusion Criteria:

  • History of illnesses or any organic abnormalities that could affect the results of the study.
  • History of abuse tobacco or alcohol or regular use of recreational or therapeutic drugs.
  • Subjects that have taken any medication within 14 days or that are in an elimination period of less than 7 half-lives (whichever is longest) before study startup.
Sexes Eligible for Study: Male
18 Years to 55 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Medical Director, Bayer de Mexico S.A. de C.V.
Not Provided
Study Director: Bayer Study Director Bayer
June 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP